Drug Candidate Improves Lung Function in Long COVID Patients
The investigational treatment improved lung function and quality of life in previously hospitalized COVID-19 patients with long-term pulmonary complications.
The investigational treatment improved lung function and quality of life in previously hospitalized COVID-19 patients with long-term pulmonary complications.
The investigational treatment improved lung function and quality of life in previously hospitalized COVID-19 patients with long-term pulmonary complications.
Read MoreThe phase 1 trial evaluates the nicotine inhaler as a smoking cessation therapy, aiming to improve nicotine delivery and support smokers in quitting.
Read MoreA phase 1 trial of the investigational therapy for H5N1 bird flu showed promising safety, tolerability, and pharmacokinetic results, with the company securing financing to advance its development.
Read MoreNovavax has begun a phase 3 trial evaluating its COVID-19-influenza combination vaccine in adults aged 65 and older.
Read MoreBenralizumab injection improved respiratory symptoms within 28 days and reduced treatment failures by fourfold after 90 days compared to standard steroid therapy.
Read MoreA clinical trial testing a smallpox antiviral for mpox was halted after interim findings showed no efficacy in reducing lesion resolution or pain in mild to moderate cases.
Read MoreA self-amplifying mRNA vaccine candidate for H5N1 avian influenza is set to begin phase 1 trials in the US after receiving FDA approval to proceed.
Read MoreThe study will evaluate the safety and tolerability of an inhaled peptide therapy designed to enhance CFTR function, act as a bronchodilator, and reduce inflammation.
Read MoreThe NIH clinical trial aims to address a knowledge gap on mpox vaccine use in adolescent populations.
Read MoreThe FDA has placed a hold on Novavax’s Investigational New Drug application for its COVID-19-influenza combination and stand-alone influenza vaccines following a report of an adverse event in a participant from the completed combination trial.
Read MoreThe trial will assess the efficacy of the drug, which has been granted orphan drug designation, when added to the standard of care in preventing or reducing the severity of bronchopulmonary dysplasia.
Read MoreNew sub-analyses show that brensocatib reduced pulmonary exacerbations and slowed lung function decline for most subgroups of patients with non-cystic fibrosis bronchiectasis.
Read MoreCumulative efficacy over three RSV seasons was clinically meaningful at 62.9% against RSV-LRTD after a single dose of the vaccine.Â
Read MoreAstraZeneca’s inhaled anti-inflammatory rescue medication demonstrated significant benefit compared to albuterol in a phase IIIb trial.
Read MoreTopline results demonstrated that the drug was well-tolerated over a 10-day period and achieved consistent plasma levels without the need for ritonavir co-administration.Â
Read MoreApnimed announced the early completion of enrollment for its phase 3 trial to evaluate the efficacy and safety of AD109 for obstructive sleep apnea.
Read MorePeople taking the drug had fewer pauses in their breathing and higher levels of oxygen in their blood during sleep.
Read MoreThe EBO-301 study is being discontinued following topline results from the phase 2 part of the study in treatment-refractory patients with MAC lung disease.
Read MoreInsmed’s brensocatib demonstrates a reduction in exacerbations and lung function decline measures compared to placebo in a 52-week phase 3 trial for non-cystic fibrosis bronchiectasis.
Read MoreThe Cleveland Clinic ReCOVer Clinic is enrolling Long COVID patients in the NIH RECOVER-VITAL clinical study.
Read MoreThe anti-inflammatory and insulin-sensitizer, which permeates the blood-brain barrier, could represent an oral treatment targeting an underlying cause of long COVID symptoms.
Read MoreA phase 3 clinical trial, ivacaftor (Kalydeco, Vertex Pharma) was generally safe to administer to infants aged 1-month to <4-months old, according to research published in Journal of Cystic Fibrosis.
Read MoreThe treatment yielded similar outcomes for egg, milk, wheat, cashew, walnut, and hazelnut.
Read MoreTheravance Biopharma’s COPD treatment Yupelri was not superior to Boehringer Ingelheim’s Spiriva Handihaler, according to results from a phase 4 study reported by Theravance.
Read More